Clinical trial
Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating…
NCT00003382 · Gynecologic Oncology Group, Other · Terminated
Key facts
| NCT number | NCT00003382 |
|---|---|
| Title | Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer |
| Official title | A Phase I Study of Gemcitabine/Topotecan in Combination in Refractory Ovarian Cancer or Cancer of the Fallopian Tube |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, gemcitabine hydrochloride, topotecan hydrochloride |
| Start date | May 1, 1998 |
| Primary completion | Apr 1, 2006 |
| First posted | Jul 15, 2003 |
| Last update posted | Jun 10, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: